Acute intermittent porphyria: a diagnostic challenge.

Vol 55, No 4 (2024)

Clinical vignette

Published online: 2024-08-29

Page views 10

Article views/downloads 3

Get Citation

Connect on Social Media

Karol Bigosiński¹

, Maciej Dubaj¹

, Aneta Szudy-Szczyrek¹

, Marek Hus¹

DOI: 10.5603/ahp.101063

Acta Haematol Pol 2024;55(4):226-227.

< p > < /p >

Keywords: acute intermittent porphyriahemeporphyrinogenic agents

Spiritos Z, Salvador S, Mosquera D, et al. Acute Intermittent Porphyria: Current Perspectives And Case Presentation. Ther Clin Risk Manag. 2019; 15: 1443–1451.
CrossRefPubMed
Bustos J, Vargas L, Quintero R. Acute intermittent porphyria: A case report. Biomedica. 2020; 40(1): 14–19.
CrossRefPubMed
Valbuena Valecillos A, Yatham P, Alderman M, et al. Acute intermittent porphyria: a review and rehabilitation perspective. Cureus. 2023; 15(8): e44260.
CrossRefPubMed
Zhao L, Wang X, Zhang X, et al. Therapeutic strategies for acute intermittent porphyria. Intractable Rare Dis Res. 2020; 9(4): 205–216.
CrossRefPubMed
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. Givosiran. 2020 Feb 27. PMID: 32200604.